Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT05539872 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetics
Pharmacodynamics

Interventions

DRUG: I004
DRUG: NovoLog

Sponsor

Amphastar Pharmaceuticals, Inc.